American Pharmacogenomics Association (APGxA)
The American Pharmacogenomics Association (APGxA) is an exclusive organization for PGx leaders dedicated to advancing the scientific understanding and application of pharmacogenomics, a field that studies how an individual’s genetic makeup influences their response to medications. A life changing movement in unity amongst leaders, business growth and quality of life, all in our one-of-a-kind community.
Download our Latest eBook
Unraveling Non-Metabolic Gene Influence on Drug Efficacy
The American Pharmacogenomics Association, now referred to as APGxA, plays a crucial role in the field of pharmacogenomics, which examines the impact of genetic makeup on drug response. As a central hub for professionals in this area, APGxA drives education, research, and collaboration, organizing events and publishing work to integrate pharmacogenomics into clinical practice. APGxA is pivotal in connecting genomic science with everyday healthcare, striving to improve patient care through personalized, effective, and safer drug therapies tailored to individual genetic profiles.
In addition to these core activities, APGxA engages in public outreach and advocacy, collaborating with stakeholders like policymakers, educational institutions, and patient groups to encourage the use of pharmacogenomic testing in clinical settings. This effort not only enhances healthcare providers’ understanding of pharmacogenomics but also empowers patients to make informed treatment decisions. APGxA’s commitment to pharmacogenomics education involves creating resources and tools for interpreting genetic testing results, thereby facilitating the practical application of pharmacogenomics in personalized healthcare. Through these initiatives, APGxA significantly contributes to transforming healthcare systems towards more personalized treatment protocols, optimized for genetic variability among patients. The APGxA has an additional International division to bring global awareness to PGx.
What we have to offer…
Membership Benefits
ADVOCACY, not mentioned to the list on the right because there is simply too much to say about it.
The American Pharmacogenomics Association (APGxA) is a key advocate for incorporating pharmacogenomics, the study of how genes influence drug responses, into healthcare. Their work includes advancing research and education in the field, developing policies and guidelines for pharmacogenomic testing, and increasing public and healthcare provider awareness about the benefits of personalized medicine. They also focus on advocating for insurance coverage for genetic testing and engaging in international collaborations to promote global standardization of pharmacogenomic practices. Through these efforts, (APGxA) is significantly enhancing the role of personalized medicine in improving patient outcomes.
The American Pharmacogenomics Association proudly partners with the Western New England University College of Pharmacy’s Master of Science in Pharmacogenomics program. Taught in the cutting-edge facilities of the Center for the Science and Pharmacy, the curriculum equips students for careers in research, the pharmaceutical sector, regulatory bodies, genetic testing labs, or clinical environments. This program offers a comprehensive foundation for those seeking to advance in the field of pharmacogenomics. Coming soon: the matching of interns from WNE University with leading companies to foster professional growth and industry experience.
EVENTS
Upcoming PGx Education
Our conference will be on March 11-13, 2025, at the Hilton Orange County/Costa Mesa hotel. Our education lineup that will unmatched, setting standards in the PGx industry. To receive more information once those are announced, sign up here:
Join our monthly PGx Coffee Talks! Casual and fun chit chat about industry happenings!
LIVE Webinar
Q2 Date TBA
Q2 Webinar Topic and
June 11, 2024 at 7:30am PST
Luma Mahairi, PharmD, PhD, MPH, MBA
Donate to Make a Difference in our Efforts
We can always use help. Our Association’s goal is to advance Pharmacogenomics, through research, availability and education. All that takes money. We appreciate all donations!
legislation
We support Bill H.R. 6875 – 17th Congress (2022)
Sponsored by Representative, Eric Swalwell, this bill sets out requirements and activities to address adverse drug events, including using pharmacogenomic testing to prevent them. (Pharmacogenomic testing uses a patient’s genetic information to help determine the safety, efficacy, and dosage of medications for treatments.)
“
Headline Sponsor
To be announced
Join us at the much anticipated 2025 APGxA’s “PGx Con”
The American Pharmacogenomics Association (APGxA) Conference on March 11-13, 2025 in Costa Mesa, California, promises to be a pivotal event in pharmacogenomics. This gathering of global experts and professionals will highlight the latest in genomic technologies and personalized medicine. Keynote speeches, interactive sessions, and networking opportunities will enrich the conference, fostering knowledge exchange and collaborations. It’s an essential platform for advancing pharmacogenomics and shaping the future of personalized healthcare. Some of the latest and most advanced testing and products will be featured as well.
Opening Keynote Speaker
Dr. Rubén Bonilla Guerrero, MD.